Octapharma's Innovations for Bleeding Disorder Management to Shine at ISTH 2024

Introduction to Octapharma's Commitment

Octapharma, a leading human protein manufacturer, is set to present groundbreaking research and innovations at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) from June 22-26, 2024, in Bangkok. This international event will spotlight Octapharma's advancements in managing rare bleeding disorders such as haemophilia A and von Willebrand disease (VWD).

Rare Bleeding Disorders: An Overview

Haemophilia A and VWD are serious conditions that can lead to frequent and severe bleeding episodes. These disorders not only threaten patients' lives but significantly impair their quality of life and mental health. Prophylactic treatments are essential in mitigating these risks and improving daily living.

Octapharma's Presentations at ISTH 2024

The congress will feature several presentations from Octapharma, showcasing their commitment to enhancing patient care. The presentations will include seven oral sessions, two poster sessions, and two supported symposia. These sessions will allow Octapharma to share their latest research findings and the practical applications of their treatments.

Key Research Findings

Among the highlighted studies is WIL-31, the largest study in VWD prophylaxis. This study demonstrated the effectiveness and safety of a plasma-derived von Willebrand factor/factor VIII concentrate in patients with VWD, supporting the use of prophylactic treatments to manage the condition.

The MOTIVATE study focuses on managing haemophilia A patients with inhibitors, emphasizing the necessity of tailored treatment plans. Initial findings of this international study indicate promising outcomes for patients.

Innovative Diagnostic Tools

Another significant development is the identification of microRNAs as biomarkers for early diagnosis of haemophilic arthropathy. Early diagnosis is crucial for preventing long-term joint damage, and this innovative approach highlights Octapharma's commitment to cutting-edge research.

Improving Endothelial Functionality

Research has also shown that Nuwiq® can enhance the functionality of endothelial cells in patients with haemophilia A. This improvement underscores the potential of Nuwiq® to offer more effective treatment for haemophilia A by ensuring better clot formation following vascular injury.

Understanding FVIII Interactions

Data indicates that FVIII interactions with platelets are vital for effective clot formation. Nuwiq® has shown superior binding to platelets compared to other products, which could lead to more effective treatments for patients with haemophilia A.

Participation and Accessibility

Both oral presentations and poster sessions are scheduled between June 23 and June 26. The congress will also include supported symposia to discuss new clinical and scientific data and answer questions from participants, both on-site in Bangkok and online.

Enhancing Patient Care in VWD

One symposium will dive deep into the importance of prophylaxis in severe VWD, including managing heavy menstrual bleeding and optimizing care during pregnancy, while introducing pivotal studies like VIP and EMPOWER.

Conclusion

Octapharma's participation in ISTH 2024 reflects its unwavering commitment to improving lives through innovative research and treatments for rare bleeding disorders.